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CD133 positive embryonal rhabdomyosarcoma stem-like cell
population is enriched in rhabdospheres
Abstract
Cancer stem cells (CSCs) have been identified in a number of solid tumors, but not yet in
rhabdomyosarcoma (RMS), the most frequently occurring soft tissue tumor in childhood. Hence, the
aim of this study was to identify and characterize a CSC population in RMS using a functional
approach. We found that embryonal rhabdomyosarcoma (eRMS) cell lines can form rhabdomyosarcoma
spheres (short rhabdospheres) in stem cell medium containing defined growth factors over several
passages. Using an orthotopic xenograft model, we demonstrate that a 100 fold less sphere cells result in
faster tumor growth compared to the adherent population suggesting that CSCs were enriched in the
sphere population. Furthermore, stem cell genes such as oct4, nanog, c-myc, pax3 and sox2 are
significantly upregulated in rhabdospheres which can be differentiated into multiple lineages such as
adipocytes, myocytes and neuronal cells. Surprisingly, gene expression profiles indicate that
rhabdospheres show more similarities with neuronal than with hematopoietic or mesenchymal stem
cells. Analysis of these profiles identified the known CSC marker CD133 as one of the genes
upregulated in rhabdospheres, both on RNA and protein levels. CD133(+) sorted cells were
subsequently shown to be more tumorigenic and more resistant to commonly used chemotherapeutics.
Using a tissue microarray (TMA) of eRMS patients, we found that high expression of CD133 correlates
with poor overall survival. Hence, CD133 could be a prognostic marker for eRMS. These experiments
indicate that a CD133(+) CSC population can be enriched from eRMS which might help to develop
novel targeted therapies against this pediatric tumor.
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population in RMS using a functional approach. We found that embryonal rhabdomyosarcoma (eRMS) cell lines can form
rhabdomyosarcoma spheres (short rhabdospheres) in stem cell medium containing defined growth factors over several
passages. Using an orthotopic xenograft model, we demonstrate that a 100 fold less sphere cells result in faster tumor
growth compared to the adherent population suggesting that CSCs were enriched in the sphere population. Furthermore,
stem cell genes such as oct4, nanog, c-myc, pax3 and sox2 are significantly upregulated in rhabdospheres which can be
differentiated into multiple lineages such as adipocytes, myocytes and neuronal cells. Surprisingly, gene expression profiles
indicate that rhabdospheres show more similarities with neuronal than with hematopoietic or mesenchymal stem cells.
Analysis of these profiles identified the known CSC marker CD133 as one of the genes upregulated in rhabdospheres, both
on RNA and protein levels. CD133+ sorted cells were subsequently shown to be more tumorigenic and more resistant to
commonly used chemotherapeutics. Using a tissue microarray (TMA) of eRMS patients, we found that high expression of
CD133 correlates with poor overall survival. Hence, CD133 could be a prognostic marker for eRMS. These experiments
indicate that a CD133+ CSC population can be enriched from eRMS which might help to develop novel targeted therapies
against this pediatric tumor.
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Introduction
The cancer stem cell hypothesis suggests that a small
subpopulation of cells sharing common characteristics with nor-
mal stem cells (SCs) - such as capacity to self renew, potential
to differentiate, extensive proliferation in vivo, and resistance
to chemotherapeutics - is responsible for tumor development
[1] and that tumors are organized hierarchically. This concept
was first established in acute myeloid leukemia (AML) [2] and
subsequently also in a number of solid tumors such as breast
cancer where a CD44+/CD242/low CSC population was iden-
tified [3], in brain tumors [4], colon cancer [5], and mela-
nomas [6]. Additionally, CSCs are postulated to be more resistant
to standard chemotherapy [7,8,9,10,11] and might be responsible
for tumor recurrence usually observed in the clinics. However,
the concept is still controversial and the frequency of CSCs
might vary between tumor entities. Some tumors might not be
hierarchically organized at all. Therefore, the existence of such a
cellular subpopulation most likely has to be established for each
tumor type [12].
Rhabdomyosarcoma (RMS) is the most common soft tissue
tumor in childhood representing 5 to 8% of all pediatric ma-
lignancies [13]. RMS is a member of the small blue round cell
tumors additionally comprised of neuroblastoma, non-Hodgkin’s
lymphoma, Ewing’s sarcoma and Wilm’s tumor [14]. It occurs in
most parts of the body, but more frequent sites are spaces
surrounding the brain, the trunk and genitourinary tract [15]. It
has been suggested that mesenchymal stem cells (MSCs) might be
the origin of rhabdomyosarcomas and accordingly the origin of
a potential rhabomyosarcoma stem cell might also be a mesen-
chymal one [16,17]. However, some reports indicate that also
neuronal cells can transform into malignant myogenic cells after
activation and a large number of neuronal genes are expressed in
RMS. Hence the origin of potential RMS stem cells remains to be
determined [18,19].
CD133, also known as Prominin1, is a five transmembrane
protein with eight potential N-glycosylation sites. It was first
described in murine neuroepithelial cells and was recognized as a
human hematopoietic SC marker, because hematopoietic CD34+
progenitor cells express CD133 [20]. CD133 has been suggested
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as CSC marker in brain tumors [21], breast [3], colon [22],
pancreatic [23], liver [24], skin [25], prostate cancers [26] and
Ewing’s sarcoma [27]. Furthermore, CD133+ glioma stem cells are
more resistant to chemotherapy and radiation than bulk and the
CD133 negative population [8]. Moreover, CD133 downregula-
tion induced differentiation in neuroblastoma cell lines and thus
increased sensitivity to drug treatment [28]. Therefore, CD133
could by itself also represent a potential marker for targeted
therapy. Nevertheless, CD133 positive CSC populations in
melanoma and prostate cancer are still controversially discussed
[29,30].
Here, we enriched for a CSC population in rhabdosphere
cultures which are 100 fold more tumorigenic than adherent cells
in xenograft experiments. This subpopulation expressed the stem
cell genes sox2, oct4, nanog, c-myc and pax3 to significantly higher
levels and retains the capability to differentiate into adipocytes,
myocytes and neuronal cells. Furthermore, the known stem cell
marker CD133 was upregulated in rhabdospheres. CD133+ cells
characterize a subpopulation which is more tumorigenic and
resistant to chemotherapy than the negative population. In ad-
dition, high CD133 expression in human eRMS samples cor-
related with a poor overall survival.
Thus, our study demonstrates for the first time that rhabdo-
spheres can be formed from eRMS cells which are enriched in a
CD133+ CSC population.
Materials and Methods
Cell culture methods
Rh36 (kindly provided by Peter Houghton (St Jude Children’s
Hospital, Memphis, TN, USA)), RD, U87MG and MRC5
(purchased from the American Type Culture collection (LGC
Promochem, Molsheim Cedex, France)) and Ruch2 (established
in house) were cultured in Dulbecco’s modified Eagle medium
containing 10% fetal calf serum (FCS).
Sphere cultures were derived from and enriched over several
passages by seeding the cell lines in a defined serum free medium
(SC medium) consisting of Neurobasal medium (Invitrogen)
supplemented with 10ng/ml EGF (R&D Systems), 20ng/ml b-
FGF (R&D Systems) and 26 B27 (10ml; Invitrogen) [31].
Adipogenesis was induced as described [32,33]. Briefly, after
preparing spheroids, cells were seeded into chamber slides and
treated with or without 0.1% DMSO for 3 days. After 8 days in
differentiation medium, containing 85nM insulin, 2nM triiodthyr-
onine (T3) and 10% FCS, cells were stained with OilRedO
(ThermoScientific) [34]. Neurogenesis and Myogenesis were
assayed as described [35]. Briefly, cells were seeded into 6 well
plates and treated with different concentrations of retinoic acid
(RA; 1nM, 10nM, 300nM). After 24 days in differentiation
medium containing RA and 0.5% FCS, cells were fixed in 4%
paraformaldehyde (PFA) and stained for differentiation markers.
Resistance to chemotherapeutics was tested by seeding 2000 cells
in a 6-well plate 48 hours before treatment. The cells were treated
twice a week with different concentrations of cisPlatin (Sigma;
10 mM and 50 mM) and Chlorambucil (Sigma; 6.45 mM). Twice a
week, colonies were counted and documented. For visualizing the
colonies, we stained them with crystal violet according to Franken,
et al. [36].
Immunofluorescence, immunohistochemistry and flow
cytometry/sorting
For immunofluorescence staining, cells were fixed in 4% PFA
and blocked in medium containing 10% FCS and 0.5% Tri-
ton. Cells were stained over night at 4uC for CD133 (1/100)
(polyclonal antibody, Abcam), GFAP (1/300) (monoclonal anti-
body, R&D Systems), myogenin (1/2) (F5D; monoclonal antibody,
Developmental Studies Hybridoma bank) and N-CAM (1/2)
(5.1H11; Developmental Studies Hybridoma bank)). Alexa Fluor
488 or 594 (1/200) (Invitrogen) antibodies were used as secondary
antibodies. All stainings were analyzed with an Axioskop2 mot
plus fluorescence microscope (Zeiss). Xenograft tumors were
embedded in paraffin, fixed and analyzed for H&E, Myogenin
(1/20) (Myf4, monoclonal antibody, Novocastra Laboratories Ltd)
and desmin (1/20) (monoclonal antibody; Dako) by immunohis-
tochemistry. As secondary antibody a horseradish peroxidase
(HRP) labeled rabbit anti-mouse antibody (Epitomics) was used.
Stainings were visualized with the Refine DAB-Kit (Leica).
For flow cytometry, cells were trypsinized, washed and stained
(1/10) with a fluorochrome labeled antibody (CD133/2-APC,
Miltenyi). All samples were measured with a BDFACSCanto II
flow cytometer (BD Bioscience) or MoFlo high speed cell sorter
(DakoCytomation) and analyzed with the software FlowJo.
Molecular methods
RNA was extracted using RNeasy Plus Mini Kits (Qiagen).
Reverse transcription was carried out using the high-capacity
cDNA reverse transcription kit (Applied Biosystems) according
to the manufacturer’s instructions. RNA and cDNA concentra-
tions were measured with a Nanodrop ND1000 spectrometer.
Quantitative Real-Time PCR was performed using vali-
dated TaqMan Gene Expression Assays (Applied Biosystems)
for POU5F1/OCT3-4 (Hs02397400_g1), NANOG (Hs023874-
00_g1), SOX2 (Hs01053049_s1), CMYC (Hs00153408_m1),
PAX3 (Hs00992437_m1), NMYC (Hs00232074_m1), PROM1/
CD133 (Hs01009261_m1) and GAPDH (Hs99999905_m1) as an
endogenous housekeeping gene for normalization. Reactions were
run using the standard conditions on an ABI 7900HT Fast Real-
Time PCR machine. Relative fold difference was calculated using
the 2DDCt method. Gene expression profiling of different RNA
samples from different sphere passages (early = passage 3; inter-
mediate = passage 5 to 7; late = passage 10) and their correspond-
ing adherent control was performed by an Affymetrix Exonmi-
croarray (HuEx-1_0-st-v2). The samples were analyzed with
the Genespring10 and Ingenuity IPA software and compared
with published data sets (hematopoietic (GSE2666), FM95
(GSE10435), embryonic skeletal myoblast (GSE3230), mesenchy-
mal stem cells (GSE2248), embryonic stem cells (GSE9440),
neuronal cells (GSE10691), glioblastoma cells and patient samples
(GSE7181), neurospheres (GSE8049) and prostate cancer samples
(GSE10832)). The correlation of the samples was analyzed with a
script programmed in R (Functional Genomic Center Zurich).
Xenograft experiments
Xenograft experiments were approved by the veterinary office
of the Canton of Zurich.
Different amounts of adherent cells and their corresponding
sphere cultures were injected intra muscularly into the right
leg of NOD.CB17-Prkdcscid/J (NOD/Scid) and NOD.Cg-Prkdcscid
Il2rgtm1Wjl/SzJ (NSG) mice (The Jackson Laboratory) and tumor
size was determined every 2 to 3 days by measuring two diameters
(d1 and d2) in right angles of both legs with a calliper. Tumor
volumes were calculated using the following formula V= [4/3 p
K(d1+d2)]right leg2[4/3 p K(d1+d2)]left leg.
Patient characteristics
76 eRMS patients, 43 male and 33 female patients, were
included from the CWS95 study. The age of the patients at
diagnosis varied from a few months to 22 years.
Cancer Stem-Like Cells in eRMS
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Figure 1. Cancer stem-like cells are enriched in Rhabdospheres. A), B) Embryonal rhabdomyosarcoma (eRMS) cell lines (RD, Rh36 and Ruch2)
were cultured in stem cell medium (SC-medium) over several passages. A glioblastoma (U87MG) and a fibroblast (MRC5) cell line were used as
controls. A) Representative phase contrast pictures of cultured RD, Ruch2 and Rh36 sphere cultures (4006 magnification). B) Subpopulation
Cancer Stem-Like Cells in eRMS
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Statistical analysis
For in vitro experiments, Student’s t test was used on triplicates.
P values of less than 0.05 were considered significant.
Results
Rhabdospheres are enriched with cancer stem-like cells
To determine whether RMS cells might contain a subpopula-
tion of CSC cells, we attempted to grow embryonal rhabdomyo-
sarcoma (eRMS) cell lines (RD, Rh36 and Ruch2) as rhabdo-
myosarcoma spheres (short rhabdospheres) in stem cell medium
(SC-medium). A glioblastoma cell line (U87MG) and fibroblast
cells (MRC5) were used as positive and negative controls,
respectively. Three eRMS cell lines (RD, Rh36 and Ruch2)
formed rhabdospheres under these conditions over several
passages (Figure 1A). To test, whether sphere cells could be
serially enriched, we seeded 20000 sphere cells over several
passages into the SC-medium and determined the number of
spheres at each passage (Figure 1B). Compared to the positive
control U87MG sphere cultures which showed the highest
enrichment over 10 passages (up to 1750 spheres per 20000 cells),
1300 spheres were counted for RD cultures after 10 passages,
while Ruch2 and Rh36 sphere cultures could also be enriched
albeit to a lesser extent (600 counted spheres) indicating that a
subpopulation of cells with self renewal property can be enriched
from three different eRMS cell lines. To investigate whether this
self renewing subpopulation is more tumorigenic than the
adherent population, we injected different numbers of RD
cells and their corresponding sphere cultures (106, 105 and 104)
intramuscularly (i.m.) into the right leg of NOD/Scid mice (n = 6)
and measured tumor growth over several weeks (Figure 1C).
Xenograft tumors from sphere cultures started to grow around day
40 after injection, compared to adherent cells where we detected
the earliest tumor growth around day 80 post injection. Moreover,
tumor growth was observed when we injected 100 fold less sphere
cells (104), whereas no tumor growth was seen using the same
number of adherent cells. 125 days after injection, in two out of six
NOD/Scid mice injected with 105 adherent cells, a small tumor
was seen, while we detected tumors in every mouse injected
with 105 sphere cells already after 60 days. These results were
subsequently confirmed in a second mouse strain, namely NSG
mice, where tumor growth was observed with 105, 104 and 103
(one out of three mice) injected sphere cells, but only with 106
adherent cells (Figure 1D). Therefore, in both mouse models cells
from sphere cultures are more tumorigenic and fewer cells are
needed for tumor growth compared to adherent cells. To
demonstrate that all xenograft tumors were indeed RMS tumors,
we collected tumor samples and constructed a xenograft tissue
microarray (TMA) with adherent RD cells and corresponding
sphere cultures as controls. Stainings of the TMA with RMS
markers, myogenin and desmin, was positive in both adherent cells
and spheres (Figure 1E) which were negative for markers of other
small blue round cell tumors (CD45, CD99, cytokeratin (CK),
S100b, Synaptosin, smooth muscle actin (SMA) and WT1; data
not shown). Furthermore, all xenograft tumors displayed typical
RMS hallmarks such as multinucleated cells and positive stainings
for desmin and myogenin, irrespective of the mouse strain they
were grown in. These results confirmed that all xenograft tumors
represented RMS tumors with similar features. We conclude from
these experiments that a subpopulation of RMS cells can be
enriched in sphere cultures over several passages which is more
tumorigenic in vivo and therefore could represent a potential CSC
population.
Sphere cultures have stem cell characteristics
To further substantiate the notion that rhabdospheres are
enriched for CSC, we quantified the expression levels of several
known SC genes like oct4, nanog, c-myc, sox2 and pax3 with real-
time PCR in different passages of sphere cultures (passages 3, 7,
10) compared to adherent cells. While oct4 and pax3 showed the
highest upregulation in RD sphere cultures (P,0.0001), also c-
myc (P = 0.0016), sox2 (P = 0.0068) and nanog (P = 0.0028) were
significantly upregulated (Figure 2A). Similar results were
obtained with Rh36 cells with the exception of pax3 and c-myc
which did not change significantly (Figure 2B). This could be due
to already high endogenous expression levels in the adherent
Rh36 cell line when compared to RD adherent cells (data not
shown). Therefore, we selected RD cells for all subsequent
experiments.
It has been shown that cells with multilineage differentiation
potential can differentiate into neuronal cells, myocytes and
adipocytes after treatment with dimethylsulfoxid (DMSO) or
retinoic acid (RA) [32,35,37,38]. On that basis, we next assessed to
which extent RD cells can be differentiated towards these line-
ages. First, we treated adherent and sphere cultures with different
concentrations of RA (1nM, 10nM and 300nM). After 24 days,
cells were stained with myogenic (myogenin, N-CAM) and
neuronal markers (GFAP, N-CAM) (Figure 2C, D). Although
adherent cells expressed low levels of myogenin (3,6% and 11,5%)
after treatment (Figure 2C), sphere cultures showed much stronger
upregulation of myogenin positivity (,50%) (Figure 2D). The
highest expression of N-CAM (52%) was detectable after
treatment with 10nM RA. While both spheres and adherent
cells were negative for myogenin when treated with 300nM RA,
we observed positive stainings for N-CAM and GFAP (9,4%),
indicative of neuronal differentiation, only in sphere cultures
(Figure 2D) and not in adherent cells (Figure 2C). In contrast, no
GFAP positive cell was found after 1 and 10nM RA treatment
(data not shown). Untreated controls were negative for all markers
analyzed (data not shown).
To differentiate cells towards adipocytes, we treated spheroids
from both adherent and sphere cells for 3 days with DMSO. After
subsequent cultivation in appropriate differentiation medium for 8
days, around 5% of DMSO treated adherent cells were positive for
fatty vacuoles (Figure 2E). However, sphere cultures had positively
stained fatty vacuoles in up to 90% (mean 73.75%) of the cells
when treated with DMSO (Figure 2E).
In conclusion, sphere cultures had a significantly increased
expression level of stem cell genes and regained the capability
to differentiate towards neurogenic, myogenic and adipogenic
lineages with appropriate stimulants. These results indicate that
stem-like cells are enriched in rhabdospheres.
enrichment over several passages (x-axis) was estimated by counting the obtained spheres per cell (y-axis). C), D) Limited dilution (106, 105 and 104) of
adherent versus sphere cells in vivo. Cells were intramuscularly (i.m.) injected into NOD/Scid (n = 6) (C) and NSG mice (n = 3) (D) at the indicated
numbers and tumor growth (y-axis; tumor volume in mm3) was measured over time (x-axis). E) Immunohistochemical (IHC) stainings of xenograft
tumor sections on a xenograft tissue microarray (TMA). Adherent and sphere cells were used as controls on the TMA. The TMA was stained for H&E
and RMS markers (desmin and myogenin). Representative IHC stainings are shown (4006magnification). The small inserts represent magnifications
of positively stained cells.
doi:10.1371/journal.pone.0019506.g001
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CD133 is upregulated in sphere cultures
To characterize sphere cultures in further detail and to identify
marker proteins specifically up- or downregulated, a gene ex-
pression profiling was performed with a human exonmicroarray
(HuEx-1_0-st-v2) for both RD and Rh36 cells and three different
passages (early, intermediate and late) of their corresponding
spheres.
In Figure 3A, a heat map of all samples is shown which revealed
that RD and Rh36 cells cluster with their corresponding sphere
cells indicating that both cell lines are more different from each
other than their different passages. Nevertheless, in total 2217
genes (upregulated 1568 genes, downregulated 649 genes) are
differentially expressed in RD spheres compared to adherent cells
with a fold change of at least two. To restrict the number of genes
and to find potential markers characterizing the rhabdospheres, a
metaanalysis with different microarray samples publicly available
(hematopoietic, FM95, embryonic skeletal myoblast, mesenchymal
stem cells, embryonic stem cells, neuronal cells, glioblastoma cells
and patient samples, neurospheres and prostate cancer samples)
was implemented. All RMS samples, both adherent and rhabdo-
spheres (red (RD) and pink (Rh36)), clustered together with
neuronal and glioblastoma cells and their spheres, and patient
samples (depicted in green) (Figure 3B). Due to this observation,
we searched for genes commonly up- or downregulated in RD and
glioblastoma sphere cultures compared to their corresponding
adherent cells with a fold change of at least two (Table 1). 31 genes
were identified and further subgrouped according to their
subcellular localization; membrane (8 genes), secreted (1 gene),
endoplasmatic reticulum ER membrane (1 gene), golgi apparatus
(1 gene), cytoplasm (12 genes) and nucleus (8 genes). In addition,
12 genes are commonly downregulated (membrane (6), secreted
(2), cytoplasm (4)). To be able to identify and isolate a putative
CSC population, we were interested mainly in membrane proteins
of which we identified 14 genes. One obvious candidate gene in
this list was CD133 or Prominin1 which is a well described SC and
CSC marker. Therefore, we validated CD133 as a potential
marker of rhabdospheres at the expression level by performing
real-time PCR (Figure 3C). In sphere cultures of both RD and
Rh36, CD133 expression was indeed significantly upregulated. To
verify these results on protein level, RD cells and spheres were
stained for CD133 and analyzed by flow cytometry (Figure 3D),
fluorescence microscopy (Figure 3E) and western blotting
(Figure 3F). In all experiments, CD133 is upregulated in rhab-
dospheres compared to adherent cells also on protein level.
These experiments suggest that CD133+ cells , a known CSC
marker, are enriched in rhabdospheres and CD133 might be a
potential CSC marker in RMS.
CD133+ RMS cells are more chemoresistant and
tumorigenic
To verify whether a CD133+ subpopulation is more tumo-
rigenic and resistant to commonly used chemotherapeutics in
RMS, we sorted RD cells for CD133 positive and negative
(CD133+, CD1332) populations (Figure 4A) and performed li-
miting dilutions by orthotopical injections into NOD/Scid mice
using adherent RD cells and unsorted bulk RD cells as controls. In
contrast to the control where the highest number of cells injected
(106 cells) developed a tumor, mice injected with CD1332 cells
(105 – 102) did not develop any tumor after 140 days. In contrast,
we could detect at least one tumor in the CD133+ injected mice
in three out of four dilutions (Figure 4B). To demonstrate that
these tumors are indeed RMS tumors, we analyzed them by
immunohistochemistry using known RMS markers as described
before. All tumors were positive for desmin and myogenin and
histologically identical with RMS tumors (Figure 4C). To inves-
tigate potential resistance to commonly used chemotherapeutics,
we seeded sorted cells at low density 48 hours before starting
treatment with cisPlatin and Chlorambucil. Cells were treated
twice a week and colonies obtained were counted after staining
with crystal violet (Figure 4D). CD133+ sorted RD cells were more
resistant to treatment and formed viable colonies which developed
significantly less in the CD1332 population.
Therefore, rhabdospheres are enriched for a CD133+ popula-
tion being more tumorigenic and resistant to cisPlatin and
Chlorambucil.
High expression of CD133 correlates with poor overall
survival
Finally, we investigated whether a CD133+ subpopulation is
also present in human patient material. To this end, we stained a
human RMS TMA, first described by Wachtel [19], for CD133.
For quantification, we scored for two variables, namely intensity of
staining and number of positive cells. The added scores were used
to classify the tumors as having negative, low, middle or high
expression. ERMS patients showing no or low to intermediate
CD133 expression showed an overall survival around 75% which
is comparable with the survival rate of translocation negative RMS
patients [39]. In contrast, patients with high expression of CD133
had a clearly worse survival (less than 50%, p= 0.0272, Figure 5A).
Representative tumor sections of high, intermediate and low
CD133 stainings are shown in Figure 5B.
These results therefore indicate that CD133 is a potential CSC
marker in eRMS that might identify eRMS patients with a poor
outcome.
Discussion
Due to a better understanding of tumor organization, new
treatment approaches that target directly a CSC population now
seem possible [22]. It has been reported that not only leukemia [2]
and carcinomas [3] have a subpopulation of cells with self renewal
properties [27], but also some sarcomas such as Ewing’s sarcoma
might follow the cancer stem cell model [1]. For the most common
sarcoma in childhood, RMS, no clear subpopulation has been
identified until now [16,17]. Therefore, we used a functional
approach to investigate whether rhabdomyosarcoma tumors might
Figure 2. Sphere cultures have stem cell characteristics. A), B) Expression analysis of stem cell genes (oct4, nanog, sox2, c-myc and pax3) by
Real-time PCR. RD (A) and Rh36 (B) adherent cells and 3 different sphere culture passages (36, 76, 106) were compared. C), D) RD cells (C) and their
corresponding sphere cultures (D) were treated with retinoic acid (1nM, 10nM, 300nM) for 24 days and stained for differentiation markers (N-CAM,
myogenin and GFAP). Percentage of positivity was calculated by counting 3 different random microscopic fields with at least 30 cells. E) RD cells and
spheres were treated with 0.1% DMSO for 3 days. After additional 8 days, cells were stained for OilRedO. Percentage of cells with fatty vacuoles was
calculated by counting 4 independent slides. Representative pictures and magnifications (small box) of OilRedO stainings are shown. For A) wwww
P,0.0001; ww P= 0.0028; w P= 0.0016; www P= 0.0068. For B) wwww P= 0.0015; ww P= 0.0281; www P= 0.0275. For E) www P= 0.0004.
Abbreviations: ns, not significant; GFAP, glial fibrillary acidic protein; N-CAM, neural cell adhesion molecule; sph, spheres; adh, adherent; DMSO,
dimethylsulfoxid.
doi:10.1371/journal.pone.0019506.g002
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have a subpopulation enriched in CSCs and are hierarchically
organized.
We first adopted a sphere forming assay to enrich a sub-
population with stem cell properties in vitro. Testing different
conditions of growth factor concentrations and media, sphere
formation over several passages could be observed only in one
condition which was described previously as a neuronal stem cell
medium [31]. Several lines of evidence then indicate that these
rhabdospheres are enriched for stem-like cells. First, limiting
dilution in two different immunosuppressed mouse strains indicate
Table 1. List of genes up- or downregulated at least two fold in RD rhabdospheres.
upregulated downregulated
Localization Chosen Gene IDs Gene Symbol Chosen Gene IDs Gene Symbol
Membrane 2535 FZD2 2674 GFRA1
7976 FZD3 3778 KCNMA1
8842 PROM1 4907 NT5E
23554 TSPAN12 7010 TEK
51678 MPP6 7057 THBS1
55704 CCDC88A 23768 FLRT2
57633 LRRN1
84216 TMEM117
Secreted 255743 NPNT 4015 LOX
7424 VEGFC
Golgi apparatus 22836 RHOBTB3
ER membrane 80055 PGAP1
Cytoplasm 2037 EPB41L2 3433 IFIT2
3157 HMGCS1 3437 IFIT3
4133 MAP2 9060 PAPSS2
6860 SYT4 10231 RCAN2
9315 C5orf13
9456 HOMER1
9735 KNTC1
54874 FNBP1L
55792 PCID2
56992 KIF15
91057 CCDC34
113263 GLCCI1
Nucleus 7552 ZNF711
9735 KNTC1
10926 DBF4
55769 ZNF83
64105 CENPK
81931 ZNF93
84250 ANKRD32
90317 ZNF616
151648 SGOL1
doi:10.1371/journal.pone.0019506.t001
Figure 3. CD133 is upregulated in sphere cultures. Gene expression profiling (HuEx-1_0-st-v2) of two eRMS cells (RD and Rh36) and spheres
(early, middle and late). A) left side: Cluster plot of RD and Rh36 cells and spheres. Right side: Analysis of RD samples. Genes, being up- or
downregulated in RD spheres with a fold change of at least 2, are shown. B) Correlation plot of a metaanalysis performed with different publicly
available expression data (hematopoietic and mesenchymal stem cells biopsies, FM95 cells, embryonic skeletal myoblast cells, embryonic stem cells,
neuronal cells, glioblastoma spheres, cells and patient samples, neurospheres and prostate cancer samples) as indicated C) Expression of CD133
mRNA quantified by real-time PCR after correction with GAPDH levels as house-keeping gene. D) Flow cytometry analysis of CD133 (blue) expression.
As controls unstained adherent and sphere cells were used, respectively (grey). E) Immunofluorescence staining of CD133 (green) of adherent and
sphere cells. The nuclei were counterstained with DAPI (blue). Fields of two independent slides with at least 50 cells each were counted and the
percentage of positive stained cells calculated. F) Western blot analysis of CD133 protein expression in adherent and sphere cells. ß-Tubulin was used
as a loading control. A representative blot is shown. For C) w P= 0.0284; ww P= 0.0079. Abbreviations: ctrl, control; MSC, mesenchymal stem cells.
doi:10.1371/journal.pone.0019506.g003
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that the rhabdosphere population is at least 100 fold more
tumorigenic than adherent cells. In contrast, culturing cell lines
representing the alveolar subtype of RMS in the same stem cell
medium leads to formation of spheres which surprisingly were not
tumorigenic after injection into immunosuppressed mice (data not
shown). Hence, it seems unlikely that media conditions themselves
were responsible for induction of the observed phenotypes and
rather selection of a preexisting subpopulation was occurring
specifically in eRMS. Second, our data analyzing expression levels
of stem cell genes in rhabdospheres compared to adherent cells
demonstrate that the stem cell genes oct4, nanog, sox2, c-myc as well
as pax3, are significantly upregulated. While sox2, nanog, and oct4
are required for induction of the pluripotent stem cell pheno-
type, c-myc expression also correlates with tumor formation and
upregulation of this oncogene could trigger the higher tumor
initiating potential [40]. Pax3 is a known developmental marker
expressed during muscle and brain development, repressed in
adult tissue and connected to tumor formation and a poor overall
survival [41,42,43].
As an additional hallmark of cancer stem cells [1], we
investigated whether rhabdospheres have the potential to dif-
ferentiate into multiple lineages. Indeed, rhabdospheres treated
with DMSO and RA, respectively, differentiate towards adipo-
genic, myogenic and neurogenic lineages similar to what has been
observed in cells with multilineage differentiation potential such as
embryonal carcinoma cells [32,33,35]. These data support the
concept that rhabdospheres contain cells with stem-like features
and that RMS tumors are hierarchical organized [1].
Figure 5. High expression of CD133 correlates with a poor survival rate. Immunofluorescence staining of a human RMS TMA with CD133
(green). Nuclei were counterstained with DAPI (blue). Two values were chosen for scoring: Staining intensity (1 = low, 2 =middle and 3=bright) and
number of positive cells (0 = 0; 1 = 1–10; 2 = 11–20; 3$21). Both values were added up to the scorings negative (0 and 1), low (2 and 3), middle (4) and
high (5 and 6). A) Stainings of representative tumor sections are shown for high, middle and low scorings. B) Overall survival of eRMS patients as
shown by a Kaplan-Meier curve. For A) ww P= 0.0272.
doi:10.1371/journal.pone.0019506.g005
Figure 4. CD133+ RMS cells are more chemoresistant and tumorigenic. A) RD cells were stained for CD133 (blue) and sorted into CD133+
(green) and CD1332 (violet) populations with a MoFlo high speed cell sorter (DakoCytomation). Unstained RD cells were used as control (grey). After
sorting the different fractions were reanalyzed by flow cytometry. B) Limited dilutions in vivo of different subpopulations (106, 105, 104, 103and 102).
Bulk stained (106) and unstained cells without sorting (106) were used as controls. Cells were injected i.m. into NOD/Scid mice (n = 4) and tumor
growth measured. Numbers indicate mice with growing tumors. C) Immunohistochemical (IHC) analysis of all xenograft tumors (H&E, Myogenin and
Desmin). Representative stainings are shown. D) Clonogenic assay with sorted subpopulations (CD133+ and CD1332). Cells were treated with cisPlatin
(IC10 = 10 mM and IC60= 50 mM) and Chlorambucil (IC10= 6.45 mM). Colonies were visualized by crystal violet. cisPlatin: mean of 3 independent
sortings 6 SEM; Chlorambucil: mean of 2 independent sortings 6 SEM. For D) ww P= 0.0377; w P= 0.0241. Abbreviations: IC, inhibitory
concentration; ctrl, control.
doi:10.1371/journal.pone.0019506.g004
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Previous studies have suggested that mesenchymal stem cells
could be the origin of RMS [17,44,45]. In contrast, our me-
taanalysis of exon microarray data with published data sets
revealed that RMS samples had an expression profile more simi-
lar to neuronal cells and patients than mesenchymal stem cells.
Furthermore, expression profiles also detected a large number of
neuronal genes being expressed in RMS biopsies [19,46,47,48]
such as pax3 which is crucial for the development of both the
myogenic and neuronal lineage [42]. Interestingly, it has been
demonstrated earlier that a population of myogenic, myf-5 positive
cells can be derived from neural tube during mouse development
[49]. These myf-5 positive cells co-express both neuronal and
muscle markers, raising the intriguing possibility that the cell of
origin of our CSC population could also be a multipotential stem
cell derived from cells in the neuronal compartment. In support of
this, it has also been described that neuronal stem cells can
differentiate into malignant muscle cells after activation [18].
However, this issue needs to be addressed further in the future.
Previous studies have shown that CD133 marks hematopoietic
stem cells [20] and cancer stem cells [29], in particular neuronal
and mesenchymal CSCs [21]. Moreover, a CD133+ population
was identified as a CSC population in sarcomas such as Ewing’s
sarcoma [27] and osteosarcoma [50] which was more resistant to
chemotherapy and radiation [7,8,9,10,11]. It was therefore not
surprising that CD133 emerged as a marker for RMS CSC in our
study as well. Interestingly, also the fraction of CD133+ cells in
both Ewing’s sarcoma and RMS seem to be similar. It has been
reported that expression of FGFR3 might mark a tumorigenic
subpopulation in RMS. However, we did not find an increase in
mRNA expression of this receptor in rhabdospheres (Figure S1).
The same report also found that CD133 positive cells were not
more tumorigenic than the negative population. However, the
discrepancy with our study might be explained by the different
CD133 epitopes that were used in the two studies. Here, using
CD133 as a marker to sort cells which were then injected
orthotopically into mice without prior cultivation in stem cell
media, we readily detected tumor growth at lower cell numbers in
CD133 positive versus CD133 negative cells. Indeed, in the
CD133+ injected group one mouse at every dilution developed a
RMS tumor which was not observed in the CD1332 population.
The relatively low tumorigenicity detected in the sorted population
in general is likely due to impaired viability of the cells by the
sorting procedure. Interestingly, CD133+ sorted cells were also
more resistant to cisPlatin and Chlorambucil treatment suggesting
that anti-apoptotic or mismatch repair proteins are active. Indeed,
we observed upregulation of several transcripts encoding mis-
match repair proteins in rhabdospheres (data not shown).
Finally, we stained a human RMS tissue microarray (TMA) [19]
for CD133 to demonstrate that a CD133+ population is also
present in human tumor biopsies. Patients with high positivity for
CD133 were found to have the worst overall survival, which could
be explained by a higher recurrence. However, in a multivariate
analysis using a cox regression model, we were not able to
demonstrate that CD133 is an independent prognostic marker for
eRMS since the number of patients in this group was too low.
More patients will have to be included therefore in a future study.
Nevertheless, CD133 might represent the first candidate marker to
identify eRMS patients with poor survival and might be used to
stratify patients in the future.
Conclusion
Overall, our results demonstrate that cells with self renewal
property that can drive tumorigenicity and have the potential to
differentiate into multiple lineages are enriched in rhabdospheres.
With CD133, we identified an already known CSC marker in an
additional sarcoma [27,50] whose expression also correlated with
a poor prognosis in eRMS patients. Further characterization
of this CD133 positive CSC population might lead to a better
understanding of the development of RMS. It now seems possible
to screen directly for therapeutically active substances targeting the
CSC subpopulation in eRMS to further advance treatment of this
childhood sarcoma.
Supporting Information
Figure S1 Prominin and fibroblast growth factor recep-
tor (FGFR) expression in adherent and sphere cells. A)
Prominin1 and Prominin2 gene expression profiles in adherent
and sphere cells analyzed by Genespring10 software. Intensity
values were normalized to adherent cells. B) FGFR1, FGFR2,
FGFR3 and FGFR4 gene expression profiles in adherent and
sphere cells. Intensity values were normalized to adherent cells.
C) Quantitative Real-time PCR with primers for FGFR3
(Hs00997400_g1) and for GAPDH was done with cDNA of adhe-
rent cells and three different passages of sphere cells. Quan-
titative results are indicated in arbitrary units (AU). FGFR3 was
not differentially expressed in sphere cells compared to adherent
cells.
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